Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure

• Egile Nagusiak: Sabine Vogler (Egilea), Peter Schneider (Egilea), Martin Zuba (Egilea), Reinhard Busse (Egilea), Dimitra Panteli (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs...